Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis

Table 2

Characteristics of the included studies on predictive and prognostic value of PD-L1 status in UC patients treated with platinum-based chemotherapy.

Study	Baras et al. (2016) [21]	Bellmunt et al. (2015) [3]	Erlmeier et al. (2016) [20]
Country	USA	USA	Germany
UC patients	MIUC	Metastatic UC	Locally advanced
Tumour stage	All stage	pT2-T4	pT3/pT4
Management	TURBT	TURBT, RC	RC
Chemotherapy	Neoadjuvant platinum-based	Adjuvant platinum-based	Adjuvant platinum-based
PD-L1 expression	Tumour cells	Tumour cells/TIICs	Tumour cells
Detection method	IHC	IHC	IHC
Cut-off value	1%, 5%	5%	10%
PD-L1+	20.6%	16.3%	35.5%
PD-L1+/-	7/34	14/86	11/31
ORR (PD-L1+/-)	42.9%/38.2%	na	37.5%/35.7%
OS rate (PD-L1+/-)	na	64.3%/39.5%	54.5%/51.6%

UC: urothelial carcinoma; MIUC: muscle-invasive UC; PD-L1: programmed death-ligand 1; +/-: positive/negative; TURBT: transurethral resection of bladder tumour; RC: radical cystectomy; TIICs: tumour-inflating immune cells; IHC: immunohistochemistry; ORR: objective response rate; OS: overall survival; pT: physical stage; na: data not available.